Home | Business News | Browse by Publication | F | Fair Disclosure Wire

ACADIA PHARMACEUTICALS INC at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference - Final.

Article Excerpt
Original Source: FD (FAIR DISCLOSURE) WIRE

ULI HACKSELL, CEO, ACADIA PHARMACEUTICALS: Thank you [Mike], and good morning. Let me first say that I'm going to make forward-looking statements today, and therefore I encourage you to read the risk factors that we have filed with the SEC.

At ACADIA, we are a CNS-focused company with a broad and deep pipeline focused on major pharmaceutical markets where there are also major medical needs. Our products address those needs better than existing products and we're very excited about how this pipeline is progressing. I also want to mention that all the programs in our pipeline emanate from discoveries that we have made at ACADIA.

This is ACADIA's pipeline. In red, you'll see our proprietary programs, and in orange, partner programs. So our most advanced program is Pimavanserin for Parkinson's disease psychosis, which in fact is in Phase III. Then we have a number of Phase II programs, Phase I programs, and additional programs that will, over time, allow us to fill our pipeline with more chemical programs.

In today's presentation, I will focus very much on the more advanced programs. But let me first tell you briefly about our commercial strategy, which is really based on the practical aspects on marketing drugs. So in an area like psychosis or Parkinson's disease psychosis, where we are active with Pimavanserin, I think it's very suitable for ACADIA to move all the way to registration and to participate in the commercialization of the drug -- to do that with a small dedicated sales force in the U.S., very effectively.

In schizophrenia and sleep, those are areas where need a large sales force, and we don't think it's practical for ACADIA to go all the way to registration on commercialization -- commercialization is alone in this area. Therefore, in products for these indications, it's our purposes to generate strong efficacy and safety data, and then, try to establish partnerships that will help us to design and complete Phase III programs and then really maximize the value of the drugs on the market.

And the third piece of our commercial strategy is the existing collaborations [with] the partners we paid for and run the development and ACADIA will receive milestones, and eventually, royalties. Let me know turn to Pimavanserin, our lead molecule, which is a very interesting drug molecule. It's selective 5-HT2A inverse agonist with an outstanding profile in terms of pharmokinetic advantages in terms of safety profile.

We have a strong intellectual property position on the drug as well. The first composition of matter patent expires first in 2021. And we think that with Pimavanserin we can address unmet medical needs for high value indications.

Let me start with schizophrenia which, I'm sure, you are aware is an area with a tremendous unmet medical need. The current drugs are not effective in all patients and they don't deal with many of the...